![]()
Apremilast is an orally available small molecule inhibitor of PDE4 being developed byCelgene for ankylosing spondylitis, psoriasis, and psoriatic arthritis.[1][2]
Celgene signs Concert pact, apremilast impresses for PsA
Celgene Corp has entered into a collaboration with Concert Pharmaceuticals which will focus on developing deuterium-modified compounds targeting cancer and inflammation. ………..read all at
The drug is currently in phase III trials for the three indications. Apremilast, an anti-inflammatory drug, specifically inhibits phosphodiesterase 4. In general the drug works on an intra-cellular basis to moderate proinflammatory and anti-inflammatory mediator production.
Apremilast is being tested for its efficacy in treating “psoriasis, psoriatic arthritis and other chronic inflammatory diseases such as ankylosing spondylitis, Behcet’s disease, and rheutmatoid arthritis.”
- Apremilast Palace Program Demonstrates Robust and Consistent Statistically Significant Clinical Benefit Across Three Pivotal Phase III Studies (PALACE-1, 2 & 3) in Psoriatic Arthritis” (Press release). Celgene Corporation. 6 September 2012. Retrieved 2012-09-10.
- “US HOT STOCKS: OCZ, VeriFone, Men’s Wearhouse, AK Steel, Celgene”. The Wall Street Journal. 6 September 2012. Retrieved 2012-09-06.
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....

Reblogged this on Srilanka-Chem.
LikeLike
Reblogged this on Med.Chem in Nepal.
LikeLike
Reblogged this on My Blog on Medicinal Chemistry.
LikeLike
Reblogged this on MariaGairos–DRUGS.
LikeLike
Reblogged this on MED.CHEM in BURMA.
LikeLike